Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells
- Authors:
- Lucas D. Lee
- Benjamin Mafura
- Johannes C. Lauscher
- Hendrik Seeliger
- Martin E. Kreis
- Jörn Gröne
View Affiliations
Affiliations: Department of General, Visceral and Vascular Surgery, Campus Benjamin Franklin, Charité‑University of Medicine Berlin, Berlin D‑12203, Germany
- Published online on: October 9, 2014 https://doi.org/10.3892/ol.2014.2592
-
Pages:
2681-2686
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Telmisartan is an angiotensin I (AT1) receptor blocker used in the treatment of essential hypertension, with partial peroxisome proliferator‑activated receptor γ (PPARγ) agonism. In prior studies, PPARγ activation led to apoptosis and cell cycle inhibition in various cancer cells. The aim of the present study was to investigate the potential antiproliferative and apoptotic effects of telmisartan by partially activating PPARγ. HT‑29, SW‑480 and SW‑620 cells were incubated with telmisartan (0.2‑5 µM) or the full agonist, pioglitazone (0.2‑5.0 µM). The antiproliferative and apoptotic effects of telmisartan in the human colon cancer cells were significant at therapeutic serum concentrations, and telmisartan exhibited a potency at least equivalent to the full PPARγ agonist, pioglitazone. The antiproliferative and apoptotic effects of pioglitazone in the human colon cancer cells were not completely deregulated by PPARγ blockade with GW9662. In the telmisartan‑treated cells, PPARγ blockade resulted in an increased antiproliferative and apoptotic effect. These effects are not entirely explained by PPARγ activation, however, possible hypotheses that require further experimental investigation are as follows: i) Ligand‑independent PPARγ activation through the activation‑function 1 domain; ii) a PPARγ‑independent mechanism; or iii) independent antiproliferative and apoptotic effects through GW9662.
View References
|
1
|
Schupp M, Janke J, Clasen R, Unger T and
Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome
proliferator-activated receptor-gamma activity. Circulation.
109:2054–2057. 2004.
|
|
2
|
Mangelsdorf DJ, Thummel C, Beato M, et al:
The nuclear receptor superfamily: the second decade. Cell.
83:835–839. 1995.
|
|
3
|
Fajas L, Fruchart JC and Auwerx J:
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from
an independent promoter. FEBS Lett. 438:55–60. 1998.
|
|
4
|
Matsuyama M, Funao K, Kuratsukuri K, et
al: Telmisartan inhibits human urological cancer cell growth
through early apoptosis. Exp Ther Med. 1:301–306. 2010.
|
|
5
|
Fajas L, Auboeuf D, Raspé E, et al: The
organization, promoter analysis, and expression of the human
PPARgamma gene. J Biol Chem. 272:18779–18789. 1997.
|
|
6
|
Bull AW: The role of peroxisome
proliferator-activated receptor gamma in colon cancer and
inflammatory bowel disease. Arch Pathol Lab Med. 127:1121–1123.
2003.
|
|
7
|
Sarraf P, Mueller E, Jones D, et al:
Differentiation and reversal of malignant changes in colon cancer
through PPARgamma. Nat Med. 4:1046–1052. 1998.
|
|
8
|
Bertz J, Dahm S, Haberland J, Kraywinkel
K, Kurth B-M and Wolf U: Spread of Cancer in Germany. Development
in the prevalence between 1990 and 2010. Robert Koch Institute;
Berlin: 2010, (In German).
|
|
9
|
Semple TU, Quinn LA, Woods LK and Moore
GE: Tumor and lymphoid cell lines from a patient with carcinoma of
the colon for a cytotoxicity model. Cancer Res. 38:1345–1355.
1978.
|
|
10
|
Kato M, Kusumi T, Tsuchida S, Tanaka M,
Sasaki M and Kudo H: Induction of differentiation and peroxisome
proliferator-activated receptor gamma expression in colon cancer
cell lines by troglitazone. J Cancer Res Clin Oncol. 130:73–79.
2004.
|
|
11
|
Stangier J, Su CA and Roth W:
Pharmacokinetics of orally and intravenously administered
telmisartan in healthy young and elderly volunteers and in
hypertensive patients. J Int Med Res. 28:149–167. 2000.
|
